Therapeutic resistance to FLT3 inhibition is driven by a novel ATM/mTOR pathway regulating oxidative phosphorylation

Hae J. Park,Mark A. Gregory,Vadym Zaberezhnyy,Andrew Goodspeed,Craig T. Jordan,Jeffrey S. Kieft,James DeGregori

DOI: https://doi.org/10.1101/2022.02.14.480468

2022-02-16

Abstract:ABSTRACT The bone marrow (BM) microenvironment has been shown to promote drug resistance in leukemic cells. In the present study, we demonstrate that BM stromal cells induce alterations in gene expression and signaling pathways in FLT3-dependent acute myeloid leukemia (AML) cells that impact the efficacy of FLT3-targeted therapy. Specifically, we discovered that restoration of mTOR signaling by BM stromal factors mediates protection of AML cells from apoptosis following FLT3 inhibition through increased expression and selective translation of oxidative phosphorylation transcripts. Addition of an mTOR inhibitor to FLT3-targeted therapy not only significantly reduced leukemic burden in the BM in vivo , but also prevented relapse. We further determined that ATM (ataxia-telangiectasia mutated) plays an essential role in BM stroma-mediated survival as a key upstream regulator of mTOR signaling. These studies reveal how the BM microenvironment promotes survival of AML cells in the face of FLT3 inhibition through maintenance of oxidative phosphorylation. SIGNIFICANCE Our results uncover a novel pathway activated by the BM microenvironment that provides protection of AML cells from therapeutic elimination following FLT3 inhibition. These studies identify candidates for combinatorial therapies designed to overcome the protective effects of BM and improve outcomes for AML patients.